Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in patients with HER2-positive operable breast cancer

被引：0
|
作者：
Musolino, Antonino [1 ]
Guarneri, Valentina [2 ]
Naldi, Nadia [1 ]
Bortesi, Beatrice [1 ]
Boggiani, Daniela [1 ]
Sgargi, Paolo [1 ]
Generali, Daniele G. [3 ]
Piacentini, Federico [4 ]
Dieci, Maria V. [2 ]
Ambroggi, Massimo [5 ]
Cagossi, Katia [6 ]
Gianni, Lorenzo [7 ]
Sarti, Samanta [8 ]
Bisagni, Giancarlo [9 ]
Frassoldati, Antonio [10 ]
Conte, Pierfranco [2 ]
Ardizzoni, Andrea [1 ]
机构：
[1] Univ Hosp Parma, Parma, Italy
[2] Univ Padua, Ist Oncol Veneto IRCCS, I-35100 Padua, Italy
[3] AO Ist Ospitalieri Cremona, Cremona, Italy
[4] Modena Univ Hosp, Modena, Italy
[5] Hosp Piacenza, Piacenza, Italy
[6] Ramazzini Hosp, Carpi, Italy
[7] Osped Infermi, Rimini, Italy
[8] Ist Sci Romagnolo Studio & Cura Tumori, Meldola, Italy
[9] Arcispedale Santa Maria Nuova IRCCS, Reggio Emilia, Italy
[10] Ferrara Univ Hosp, Ferrara, Italy
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3-06-23
引用
收藏
页数：2
相关论文
共 50 条
  • [41] A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment
    Bora Lim
    Rashmi K. Murthy
    Jangsoon Lee
    Summer A. Jackson
    Toshiaki Iwase
    Darren W. Davis
    Jie S. Willey
    Jimin Wu
    Yu Shen
    Debu Tripathy
    Ricardo Alvarez
    Nuhad K. Ibrahim
    Abenaa M. Brewster
    Carlos H. Barcenas
    Powel H. Brown
    Sharon H. Giordano
    Stacy L. Moulder
    Daniel J. Booser
    Jeffrey A. Moscow
    Richard Piekarz
    Vicente Valero
    Naoto T. Ueno
    British Journal of Cancer, 2019, 120 : 1105 - 1112
  • [42] Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients
    Montemurro, Filippo
    Rossi, Valentina
    Rocca, Maria Cossu
    Martinello, Rossella
    Verri, Elena
    Redana, Stefania
    Adamoli, Laura
    Valabrega, Giorgio
    Sapino, Anna
    Aglietta, Massimo
    Viale, Giuseppe
    Goldhirsch, Aron
    Nole, Franco
    CANCER, 2012, 118 (01) : 17 - 26
  • [43] CHER LOB Trial: Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer-Safety report as per Independent Data Monitoring Committee (IDMC) and preliminary activity data
    Guarneri, V.
    Frassoldati, A.
    Cagossi, K.
    Bottini, A.
    Michelotti, A.
    Cavanna, L.
    Jovic, G.
    Piacentini, F.
    Oliva, C.
    Conte, P. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [44] Clinical observation of lapatinib versus continued use of trastuzumab for trastuzumab-resistant HER2-positive advanced breast cancer
    Yin, Yongmei
    Li, Wei
    Huang, Xiang
    Wang, Jian
    Fu, Ziyi
    Li, Jun
    CANCER RESEARCH, 2018, 78 (04)
  • [45] Immunoglobulin G fragment C gamma receptor (FcGR) polymorphisms and efficacy of single-agent trastuzumab in patients treated with metastatic breast cancer
    Shimizu, C.
    Tamura, K.
    Koizumi, F.
    Aogi, K.
    Kinoshita, T.
    Fujiwara, Y.
    CANCER RESEARCH, 2009, 69 (02) : 368S - 370S
  • [46] A Phase II Preoperative Trial of Concurrent Trastuzumab and Paclitaxel without Anthracycline in HER2-Positive Operable Breast Cancer
    Sato, T.
    Hayashida, T.
    Takahashi, M.
    Sakata, M.
    Jinno, H.
    Hirose, S.
    Mukai, M.
    Kitagawa, Y.
    CANCER RESEARCH, 2010, 70
  • [47] Assessment of clinical benefit with trastuzumab plus chemotherapy (CT) in patients with HER2-positive (HER2+) metastatic breast cancer not achieving objective responses
    Pegram, Mark
    Yeon, Christina
    Patel, Ravi
    Cartmell, Alan
    Leyland-Jones, Brian
    Klein, Pam
    Eiermann, Wolfgang
    Wolter, Janet
    Lieberman, Grazyna
    Slamon, Dennis
    ANNALS OF ONCOLOGY, 2004, 15 : 29 - 30
  • [48] Immunohistochemical Features Associated with Sensitivity to Lapatinib-plus-Capecitabine and Resistance to Trastuzumab in HER2-positive Breast Cancer
    Cha, Yongjun
    Han, Sae-Won
    Seol, Hyesil
    Oh, Do-Youn
    Im, Seock-Ah
    Bang, Yung-Jue
    Park, In Ae
    Han, Wonshik
    Noh, Dong-Young
    Kim, Tae-You
    ANTICANCER RESEARCH, 2014, 34 (08) : 4275 - 4280
  • [49] Rechallenge of trastuzumab-based therapy in HER2-positive breast cancer patients who progressed after lapatinib plus capecitabine
    Khanmammadov, Nijat
    Dogan, Izzet
    Khishigsuren, Bayarmaa
    Azizy, Abdulmunir
    Saip, Pinar
    Aydiner, Adnan
    MEDICINE, 2025, 104 (06)
  • [50] Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for HER2-positive breast cancer: a prospective cohort study
    Liu, Lu
    Zhu, Mingzhi
    Wang, Yanyan
    Li, Muhan
    Gu, Yuanting
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2023, 21 (01)
12345